Extrahepatic oligonucleotide programs introduce distinct CMC challenges that differ from established liver targeted platforms. This session will examine manufacturing considerations specific to extrahepatic applications, including tighter impurity control, advanced purification requirements, stability challenges, and evolving analytical expectations. Participants will discuss how sequence design, backbone chemistry, and conjugation strategies impact process robustness and regulatory readiness. The discussion will emphasize aligning discovery and translational decisions with downstream manufacturing feasibility, and how CMC teams are adapting control strategies to support emerging tissue targets and novel delivery mechanisms.